Back to search results

ACT WONDER²S: Increasing Diversity in Cancer Clinical Trials

This study, called ACT WONDER²S, is looking at different ways to increase the number of Black and Hispanic patients who join cancer treatment clinical trials at Moffitt Cancer Center. It's testing several approaches, including Continuing Medical Education Events (CME) for doctors, a digital tool called Trial Connect Portal to help refer patients, Clinical Trial Newsletters, Implicit Bias Training for staff, and a Recruitment Dashboard to track patient diversity. The study aims to see if these interventions can successfully increase the enrollment of Black and Hispanic patients in National Cancer Institute (NCI)-sponsored cancer treatment trials over two years. You may be able to participate if you are 18 years or older and live in certain community areas, or if you are a community physician practicing in those areas. The current recruitment status is unclear.

Study design
This study uses a cluster randomized design, meaning groups of geographic areas are randomly assigned to receive the intervention or to be a control group. The study plans to enroll 7649 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal of the study is measured at 2 years, focusing on patient enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06560398

Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)

Recruiting
NAAges 18+InterventionalHealth services
H. Lee Moffitt Cancer Center and Research Institute
~7,649 participants
Updated 2026-04-01 on ClinicalTrials.gov
What's tested:Continuing Medical Education Events (CME)Trial Connect PortalClinical Trial NewslettersImplicit Bias TrainingRecruitment DashboardPortfolio Profiler

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Enrollment of Black and Hispanic Patients to NCI-sponsored cancer treatment clinical trials
Measured over 2 years

Conditions

Cancer

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Susan Vadaparampil, PhD · PRINCIPAL_INVESTIGATOR · Moffitt Cancer Center
  • Dana Rollison, PhD · PRINCIPAL_INVESTIGATOR · Moffitt Cancer Center

Who to contact

Rossybelle Amorrortu, MPH
[email protected]
813-745-4007
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Community residents: Community residents may engage with various intervention components deployed in the intervention priority zones.
Community Physicians: may engage with various intervention components deployed in the intervention priority zones if they 1) practice medicine in one of the geographic priority zones.
Cancer Center Physicians: may engage with various intervention components if they 1) practice medicine at Moffitt.
Clinical Research Coordinators (CRC): may engage with various intervention components if they 1) work as a CRC at Moffitt and 2) coordinate/pre-screen patients for at least 1 therapeutic clinical trial at Moffitt.
Cancer Center Patients: may engage with various intervention components if they have an address that maps to an intervention priority zone and 2) are newly registered patients or new existing patients (NEPs).

What this trial measures

  • Enrollment of Black and Hispanic Patients to NCI-sponsored cancer treatment clinical trials2 years

    Intervention impact on enrollment rates will be measured by comparing the percentage of Moffitt patients enrolled on NCI-supported treatment trials who are Black or Hispanic between intervention priority zones and the control priority zones.